EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 21-Jun-2026 16:15 ET (21-Jun-2026 20:15 GMT/UTC)

9-Feb-2026

Physical pressure on the brain triggers neurons’ self-destruction programming

University of Notre Dame
Peer-Reviewed Publication

An interdisciplinary team of researchers from the University of Notre Dame is investigating the mechanisms of neuron death caused by chronic compression — such as the pressure exerted by a brain tumor — to better understand how to prevent neuron loss.

Journal: Proceedings of the National Academy of Sciences

9-Feb-2026

IRB Barcelona launches Spain’s first fully integrated Spatial Omics Platform

Institute for Research in Biomedicine (IRB Barcelona)
Business Announcement

IRB Barcelona inaugurates the country’s first end-to-end fully integrated spatial omics platform, enabling scientists to map biological activity directly within its original tissue context.

The Institute has invested more than €3 million to equip the platform with the latest spatial transcriptomics and spatial proteomics technologies, along with advanced image analysis and bioinformatics capabilities.

This strategic initiative unites five specialised Core Facilities to create a coordinated, end-to-end workflow supporting research and innovation across academic, clinical, and industry partners in Spain and beyond.

9-Feb-2026

Study shows advanced PET/CT imaging can help improve long-term outcomes for men with recurrent prostate cancer

University of California - Los Angeles Health Sciences
Peer-Reviewed Publication

A five-year retrospective study shows that prostate-specific membrane antigen (PSMA) PET/CT scans can help doctors target treatment more precisely for men whose prostate cancer returns after surgery, improving long-term outcomes and potentially reducing unnecessary side effects.

Journal: Journal of the National Comprehensive Cancer Network

9-Feb-2026

Dana-Farber research helps drive FDA label update for primary CNS lymphoma

Dana-Farber Cancer Institute
Business Announcement

Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system lymphoma, a rare and aggressive lymphoma of the brain and spinal cord. The change is expected to expand access to commercial CAR T-cell therapy for eligible patients with relapsed or refractory disease.

9-Feb-2026

Early diagnosis key to improving childhood cancer survival

University College London
Peer-Reviewed Publication

Childhood cancers, survival rates, early diagnosis, comparing rates by geographical region

Journal: JAMA Network Open
Funder: CHILDREN with CANCER UK, Associazione Italiana per la Ricerca sul Cancro, National Institute for Health Research

9-Feb-2026

First in-human study finds novel immune cell therapy is safe and effective in advanced lymphoma

University of Texas M. D. Anderson Cancer Center
Reports and Proceedings

In a first-in-human study, researchers at The University of Texas MD Anderson Cancer Center observed strong responses and early signs of antitumor activity in patients with difficult-to-treat non-Hodgkin lymphomas who received the novel cell therapy RB-1355. The therapy was effective for those who have relapsed after multiple treatments or no longer responded to standard-of-care options, such as CAR T cell therapy.

9-Feb-2026

Mayo Clinic study finds chemotherapy before surgery improves survival in early-stage pancreatic cancer

Mayo Clinic
Peer-Reviewed Publication

A Mayo Clinic study is providing new insights into how treatment sequence can affect survival in patients with early-stage pancreatic cancer, suggesting that many patients may benefit from receiving chemotherapy before surgery.

Journal: Journal of the National Comprehensive Cancer Network

9-Feb-2026

Let’s get on pancreatic cancer’s nerves

Cold Spring Harbor Laboratory
Peer-Reviewed Publication

Cold Spring Harbor Laboratory postdoc Jeremy Nigri and colleagues in the Tuveson lab have discovered that the nervous system plays an active role in pancreatic cancer development—even before tumor formation. Disrupting interactions between nerves and fibroblasts could lead to new treatments or make standard procedures like chemo and immunotherapy more effective.

Journal: Cancer Discovery
Funder: Defense Health Agency, Thompson Foundation, Pershing Square Foundation, Simons Foundation, Cold Spring Harbor Laboratory, Northwell Health, U.S. Department of Defense, Pancreatic Cancer Action Network, Donaldson Foundation

9-Feb-2026

Simple blood test may help identify colorectal cancer patients at higher risk for recurrence and death

H. Lee Moffitt Cancer Center & Research Institute
Peer-Reviewed Publication

A new study led by researchers at Moffitt Cancer Center found that blood-based DNA markers known as protein epiScores can help predict which colorectal cancer patients face a higher risk of cancer recurrence or death. Results of the study were published in Clinical Epigenetics.

Researchers identified four protein epiScores that were strongly associated with worse outcomes, with patients showing higher levels experiencing a 60% to 70% greater risk of recurrence. One marker, LGALS3BP, was also linked to overall survival, with higher scores associated with an 80% increased risk of death during follow-up.

Journal: Clinical Epigenetics

9-Feb-2026

New study in JNCCN unlocks important information about how to treat recurring prostate cancer

National Comprehensive Cancer Network
Peer-Reviewed Publication

According to new research in JNCCN, information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to predict progression-free survival (PFS) and guide treatment planning in patients with rising prostate-specific antigen (PSA) levels following removal of the prostate.

Journal: Journal of the National Comprehensive Cancer Network